Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

  • Tae-Han Kim (Department of Surgery, Gyeongsang National University Changwon Hospital) ;
  • In-Ho Kim (Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Seung Joo Kang (Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center) ;
  • Miyoung Choi (National Evidence-based Healthcare Collaborating Agency (NECA)) ;
  • Baek-Hui Kim (Department of Pathology, Korea University Guro Hospital) ;
  • Bang Wool Eom (Center for Gastric Cancer, National Cancer Center) ;
  • Bum Jun Kim (Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center Hallym University College of Medicine) ;
  • Byung-Hoon Min (Department of Medicine, Samsung Medical Center) ;
  • Chang In Choi (Department of Surgery, Pusan National University Hospital) ;
  • Cheol Min Shin (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Chung Hyun Tae (Department of Internal Medicine, Ewha Woman's University College of Medicine) ;
  • Chung sik Gong (Division of Gastrointestinal Surgery, Department of Surgery, Asan Medical Center and University of Ulsan College of Medicine) ;
  • Dong Jin Kim (Department of Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Arthur Eung-Hyuck Cho (Department of Nuclear Medicine, Severance Hospital) ;
  • Eun Jeong Gong (Department of Internal Medicine, Hallym University College of Medicine) ;
  • Geum Jong Song (Department of Surgery, Soonchunhyang University) ;
  • Hyeon-Su Im (Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Hye Seong Ahn (Department of Surgery, Seoul Metropolitan Government-Seoul National University Boramae Medical Center) ;
  • Hyun Lim (Department of Gastroenterology, Hallym University Sacred Heart Hospital, University of Hallym College of Medicine) ;
  • Hyung-Don Kim (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jae-Joon Kim (Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital) ;
  • Jeong Il Yu (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University, School of Medicine) ;
  • Jeong Won Lee (Department of Nuclear Medicine, Catholic Kwandong University, College of Medicine) ;
  • Ji Yeon Park (Department of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University) ;
  • Jwa Hoon Kim (Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Kyoung Doo Song (Department of Radiology, Samsung Medical Center, Sungkyunkwan University) ;
  • Minkyu Jung (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System) ;
  • Mi Ran Jung (Department of Surgery, Chonnam National University Medical School) ;
  • Sang-Yong Son (Department of Surgery, Ajou University School of Medicine) ;
  • Shin-Hoo Park (Department of Surgery, Korea University Anam Hospital) ;
  • Soo Jin Kim (Department of Radiology, National Cancer Center) ;
  • Sung Hak Lee (Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Tae-Yong Kim (Department of Internal Medicine, Seoul National University Hospital) ;
  • Woo Kyun Bae (Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital) ;
  • Woong Sub Koom (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Yeseob Jee (Department of Surgery, Dankook University Hospital) ;
  • Yoo Min Kim (Department of Surgery, Severance Hospital) ;
  • Yoonjin Kwak (Department of Pathology, Seoul National University Hospital) ;
  • Young Suk Park (Department of Surgery, Seoul National University Bundang Hospital) ;
  • Hye Sook Han (Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine) ;
  • Su Youn Nam (Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University) ;
  • Seong-Ho Kong (Department of Surgery, Seoul National University Hospital and Seoul National University College of Medicine Cancer Research Institute) ;
  • The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2022 Task Force Team (The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2022 Task Force Team)
  • Received : 2023.01.12
  • Accepted : 2023.01.25
  • Published : 2023.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline.

Keywords

Acknowledgement

We especially express our sincere gratitude to the advisory committee: Jun Haeng Lee, Keun Won Ryu, and Sun Young Rha for counseling; Hwa Kyung Byun for contributing as an active investigator in radiation oncology; Keun-Wook Lee for internal review; Chang Hee Cho for contribution as librarian; and Jie Hye Kim for communication and secretarial contribution.

References

  1. International Agency for Research on Cancer. Cancer fact sheet stomach: Globocan 2020 [Internet]. Geneva: World Health Organization; 2022. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf.
  2. Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat 2021;53:301-315. https://doi.org/10.4143/crt.2021.291
  3. National Cancer Center, Korea Central Cancer Registry. Korean Cancer Report 2020. Goyang: National Cancer Center; 2022.
  4. Park SH, Kang MJ, Yun EH, Jung KW. Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea Central Cancer Registry Data (1999-2019). J Gastric Cancer 2022;22:160-168. https://doi.org/10.5230/jgc.2022.22.e21
  5. Information Committee of the Korean Gastric Cancer Association. Korean Gastric Cancer Association-led nationwide survey on surgically treated gastric cancers in 2019. J Gastric Cancer 2021;21:221-235. https://doi.org/10.5230/jgc.2021.21.e27
  6. World Cancer Research Fund Network. Diet, nutrition, physical activity and stomach cancer [Internet]. London: World Cancer Research Fund Network; 2018. Available from: https://www.wcrf.org/wp-content/uploads/2021/02/stomach-cancer-report.pdf.
  7. Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011;22:375-387. https://doi.org/10.1007/s10552-010-9707-2
  8. Dalmartello M, Turati F, Zhang ZF, Lunet N, Rota M, Bonzi R, et al. Allium vegetables intake and the risk of gastric cancer in the Stomach cancer Pooling (StoP) Project. Br J Cancer 2022;126:1755-1764. https://doi.org/10.1038/s41416-022-01750-5
  9. Cai H, Sobue T, Kitamura T, Ishihara J, Nanri A, Mizoue T, et al. Low-carbohydrate diet and risk of cancer incidence: The Japan Public Health Center-based prospective study. Cancer Sci 2022;113:744-755. https://doi.org/10.1111/cas.15215
  10. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48. https://doi.org/10.5230/jgc.2019.19.e8
  11. Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer 2014;14:87-104. https://doi.org/10.5230/jgc.2014.14.2.87
  12. The Korean Gastric Cancer Association. Korean guideline for gastric cancer. J Korean Gastric Cancer Assoc 2004;4:286-293. https://doi.org/10.5230/jkgca.2004.4.4.286
  13. GRADE Working Group. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [Internet]. GRADE Working Group; 2013. Available from:https://gdt.gradepro.org/app/handbook/handbook.html.
  14. Suh YS, Yang HK. Screening and early detection of gastric cancer: east versus west. Surg Clin North Am 2015;95:1053-1066. https://doi.org/10.1016/j.suc.2015.05.012
  15. Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011;98:255-260. https://doi.org/10.1002/bjs.7310
  16. Suh YS, Lee J, Woo H, Shin D, Kong SH, Lee HJ, et al. National cancer screening program for gastric cancer in Korea: nationwide treatment benefit and cost. Cancer 2020;126:1929-1939. https://doi.org/10.1002/cncr.32753
  17. Jun JK, Choi KS, Lee HY, Suh M, Park B, Song SH, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology 2017;152:1319-1328.e7. https://doi.org/10.1053/j.gastro.2017.01.029
  18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112. https://doi.org/10.1007/s10120-011-0041-5
  19. Hayes T, Smyth E, Riddell A, Allum W. Staging in esophageal and gastric cancers. Hematol Oncol Clin North Am 2017;31:427-440. https://doi.org/10.1016/j.hoc.2017.02.002
  20. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev 2015;2015:CD009944.
  21. Lee S, Jun JK, Suh M, Park B, Noh DK, Jung KW, et al. Gastric cancer screening uptake trends in Korea:results for the National Cancer Screening Program from 2002 to 2011: a prospective cross-sectional study. Medicine (Baltimore) 2015;94:e533.
  22. Ryu JE, Choi E, Lee K, Jun JK, Suh M, Jung KW, et al. Trends in the performance of the Korean National Cancer Screening Program for gastric cancer from 2007 to 2016. Cancer Res Treat 2022;54:842-849. https://doi.org/10.4143/crt.2021.482
  23. Luu XQ, Lee K, Jun JK, Suh M, Jung KW, Choi KS. Effect of gastric cancer screening on long-term survival of gastric cancer patients: results of Korean national cancer screening program. J Gastroenterol 2022;57:464-475. https://doi.org/10.1007/s00535-022-01878-4
  24. Chong CS, Ng CW, Shabbir A, Kono K, So JB. Computed tomography of the thorax for gastric cancer staging: is it necessary? Scand J Surg 2015;104:244-247. https://doi.org/10.1177/1457496915571400
  25. Chen AH, Chan WH, Lee YH, Tseng JH, Yeh TS, Chiu CT, et al. Routine chest CT for staging of gastric cancer. Br J Surg 2019;106:1197-1203. https://doi.org/10.1002/bjs.11186
  26. Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study. Ann Surg 2021;274:120-127. https://doi.org/10.1097/SLA.0000000000003499
  27. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013;14:e535-e547. https://doi.org/10.1016/S1470-2045(13)70436-4
  28. Choi JI, Joo I, Lee JM. State-of-the-art preoperative staging of gastric cancer by MDCT and magnetic resonance imaging. World J Gastroenterol 2014;20:4546-4557. https://doi.org/10.3748/wjg.v20.i16.4546
  29. Bhandari S, Shim CS, Kim JH, Jung IS, Cho JY, Lee JS, et al. Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: a comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc 2004;59:619-626. https://doi.org/10.1016/S0016-5107(04)00169-5
  30. Kim HJ, Kim AY, Oh ST, Kim JS, Kim KW, Kim PN, et al. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. Radiology 2005;236:879-885. https://doi.org/10.1148/radiol.2363041101
  31. Shimizu K, Ito K, Matsunaga N, Shimizu A, Kawakami Y. Diagnosis of gastric cancer with MDCT using the water-filling method and multiplanar reconstruction: CT-histologic correlation. AJR Am J Roentgenol 2005;185:1152-1158. https://doi.org/10.2214/AJR.04.0651
  32. Hur J, Park MS, Lee JH, Lim JS, Yu JS, Hong YJ, et al. Diagnostic accuracy of multidetector row computed tomography in T- and N staging of gastric cancer with histopathologic correlation. J Comput Assist Tomogr 2006;30:372-377. https://doi.org/10.1097/00004728-200605000-00005
  33. Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. Radiology 2007;242:472-482. https://doi.org/10.1148/radiol.2422051557
  34. Yang DM, Kim HC, Jin W, Ryu CW, Kang JH, Park CH, et al. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: histological correlation. J Comput Assist Tomogr 2007;31:98-103. https://doi.org/10.1097/01.rct.0000234072.16209.ab
  35. Yan C, Zhu ZG, Yan M, Zhang H, Pan ZL, Chen J, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol 2009;100:205-214. https://doi.org/10.1002/jso.21316
  36. Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol 2010;25:512-518. https://doi.org/10.1111/j.1440-1746.2009.06106.x
  37. Moschetta M, Stabile Ianora AA, Anglani A, Marzullo A, Scardapane A, Angelelli G. Preoperative T staging of gastric carcinoma obtained by MDCT vessel probe reconstructions and correlations with histological findings. Eur Radiol 2010;20:138-145. https://doi.org/10.1007/s00330-009-1482-7
  38. Furukawa K, Miyahara R, Itoh A, Ohmiya N, Hirooka Y, Mori K, et al. Diagnosis of the invasion depth of gastric cancer using MDCT with virtual gastroscopy: comparison with staging with endoscopic ultrasound. AJR Am J Roentgenol 2011;197:867-875. https://doi.org/10.2214/AJR.10.5872
  39. Kim JW, Shin SS, Heo SH, Choi YD, Lim HS, Park YK, et al. Diagnostic performance of 64-section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual. Eur Radiol 2012;22:654-662. https://doi.org/10.1007/s00330-011-2283-3
  40. Kumano S, Okada M, Shimono T, Kuwabara M, Yagyu Y, Imaoka I, et al. T-staging of gastric cancer of airfilling multidetector-row CT: comparison with hydro-multidetector-row CT. Eur J Radiol 2012;81:2953-2960. https://doi.org/10.1016/j.ejrad.2011.12.039
  41. Feng XY, Wang W, Luo GY, Wu J, Zhou ZW, Li W, et al. Comparison of endoscopic ultrasonography and multislice spiral computed tomography for the preoperative staging of gastric cancer - results of a single institution study of 610 Chinese patients. PLoS One 2013;8:e78846.
  42. Wani AH, Parry AH, Feroz I, Choh NA. Preoperative staging of gastric cancer using computed tomography and its correlation with histopathology with emphasis on multi-planar reformations and virtual gastroscopy. J Gastrointest Cancer 2021;52:606-615. https://doi.org/10.1007/s12029-020-00436-6
  43. Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol 2013;68:251-255. https://doi.org/10.1016/j.crad.2012.07.015
  44. Jeong J, Cho I, Kong E, Chun K, Jang B, Kim T, et al. Evaluation of hybrid PET/CT gastrography in gastric cancer. Nucl Med (Stuttg) 2013;52:107-112. https://doi.org/10.1055/s-0038-1631532
  45. Kim JE, Lee MW, Moon JW, Song KD, Park Y, Park MJ, et al. CT detection of dry peritoneal seeding in patients with advanced gastric cancer. Hepatogastroenterology 2012;59:2202-2206.
  46. Kim SJ, Kim HH, Kim YH, Hwang SH, Lee HS, Park DJ, et al. Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology 2009;253:407-415. https://doi.org/10.1148/radiol.2532082272
  47. Pan Z, Zhang H, Yan C, Du L, Ding B, Song Q, et al. Determining gastric cancer resectability by dynamic MDCT. Eur Radiol 2010;20:613-620. https://doi.org/10.1007/s00330-009-1576-2
  48. Perlaza P, Ortin J, Pages M, Buxo E, Fernandez-Esparrach G, Colletti PM, et al. Should 18F-FDG PET/CT be routinely performed in the clinical staging of locally advanced gastric adenocarcinoma? Clin Nucl Med 2018;43:402-410. https://doi.org/10.1097/RLU.0000000000002028
  49. Mao Y, Chen B, Wang H, Zhang Y, Yi X, Liao W, et al. Diagnostic performance of magnetic resonance imaging for colorectal liver metastasis: a systematic review and meta-analysis. Sci Rep 2020;10:1969.
  50. Huang Z, Xie DH, Guo L, Hu CH, Fang X, Meng Q, et al. The utility of MRI for pre-operative T and N staging of gastric carcinoma: a systematic review and meta-analysis. Br J Radiol 2015;88:20140552.
  51. Laghi A, Bellini D, Rengo M, Accarpio F, Caruso D, Biacchi D, et al. Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. Radiol Med (Torino) 2017;122:1-15. https://doi.org/10.1007/s11547-016-0682-x
  52. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: insights from the past decade. Pharmacol Ther 2013;137:318-330. https://doi.org/10.1016/j.pharmthera.2012.11.003
  53. Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MP, et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol 2018;106:128-136. https://doi.org/10.1016/j.ejrad.2018.07.010
  54. Chen Y, Zhang D, Fan K. Diagnostic accuracy of F18-fluorodeoxyglucose positron emission tomographycomputed tomography for the detection of non-small cell lung cancer recurrence: a systematic review and meta-analysis. Curr Med Imaging. Forthcoming 2022.
  55. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295. https://doi.org/10.1007/s00259-002-1029-5
  56. Yun M. Imaging of gastric cancer metabolism using 18 F-FDG PET/CT. J Gastric Cancer 2014;14:1-6. https://doi.org/10.5230/jgc.2014.14.1.1
  57. Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, et al. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. Gastric Cancer 2016;19:421-430. https://doi.org/10.1007/s10120-015-0504-1
  58. Kim EY, Lee WJ, Choi D, Lee SJ, Choi JY, Kim BT, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol 2011;79:183-188. https://doi.org/10.1016/j.ejrad.2010.02.005
  59. Lee SJ, Lee WW, Yoon HJ, Lee HY, Lee KH, Kim YH, et al. Regional PET/CT after water gastric inflation for evaluating loco-regional disease of gastric cancer. Eur J Radiol 2013;82:935-942. https://doi.org/10.1016/j.ejrad.2013.01.014
  60. Namikawa T, Okabayshi T, Nogami M, Ogawa Y, Kobayashi M, Hanazaki K. Assessment of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. Int J Clin Oncol 2014;19:649-655. https://doi.org/10.1007/s10147-013-0598-6
  61. Park K, Jang G, Baek S, Song H. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori 2014;100:201-206. https://doi.org/10.1177/030089161410000214
  62. Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, et al. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Medicine (Baltimore) 2015;94:e864.
  63. Okumura Y, Aikou S, Onoyama H, Jinbo K, Yamagata Y, Mori K, et al. Evaluation of 18F-FDG uptake for detecting lymph node metastasis of gastric cancer: a prospective pilot study for one-to-one comparison of radiation dose and pathological findings. World J Surg Oncol 2015;13:327.
  64. Lee DH, Kim SH, Joo I, Hur BY, Han JK. Comparison between 18F-FDG PET/MRI and MDCT for the assessment of preoperative staging and resectability of gastric cancer. Eur J Radiol 2016;85:1085-1091. https://doi.org/10.1016/j.ejrad.2016.03.015
  65. Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Yoshiura T. FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT. Abdom Radiol (NY) 2016;41:1891-1898. https://doi.org/10.1007/s00261-016-0788-6
  66. Lehmann K, Eshmuminov D, Bauerfeind P, Gubler C, Veit-Haibach P, Weber A, et al. 18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. Eur J Surg Oncol 2017;43:196-202. https://doi.org/10.1016/j.ejso.2016.08.020
  67. Kudou M, Kosuga T, Kubota T, Okamoto K, Komatsu S, Shoda K, et al. Value of preoperative PET-CT in the prediction of pathological stage of gastric cancer. Ann Surg Oncol 2018;25:1633-1639. https://doi.org/10.1245/s10434-018-6455-0
  68. Bosch KD, Chicklore S, Cook GJ, Davies AR, Kelly M, Gossage JA, et al. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. Eur J Nucl Med Mol Imaging 2020;47:759-767. https://doi.org/10.1007/s00259-019-04429-x
  69. Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, et al. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging 2022;49:732-742. https://doi.org/10.1007/s00259-021-05441-w
  70. Roedl JB, Prabhakar HB, Mueller PR, Colen RR, Blake MA. Prediction of metastatic disease and survival in patients with gastric and gastroesophageal junction tumors: the incremental value of PET-CT over PET and the clinical role of primary tumor volume measurements. Acad Radiol 2009;16:218-226. https://doi.org/10.1016/j.acra.2008.06.004
  71. Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol 2010;136:1929-1935. https://doi.org/10.1007/s00432-010-0852-5
  72. Smyth E, Schoder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012;118:5481-5488. https://doi.org/10.1002/cncr.27550
  73. Findlay JM, Antonowicz S, Segaran A, El Kafsi J, Zhang A, Bradley KM, et al. Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. Eur Radiol 2019;29:2490-2498. https://doi.org/10.1007/s00330-018-5904-2
  74. Debiec K, Wydmanski J, d'Amico A, Gorczewska I, Krzywon A, Cortez AJ, et al. The application of 18F-FDGPET/CT in gastric cancerstaging and factors affecting its sensitivity. Hell J Nucl Med 2021;24:66-74.
  75. Gertsen EC, Brenkman HJ, van Hillegersberg R, van Sandick JW, van Berge Henegouwen MI, Gisbertz SS, et al. 18F-fludeoxyglucose-positron emission tomography/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective Dutch cohort study (PLASTIC). JAMA Surg 2021;156:e215340.
  76. Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, et al. The role of 18F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging 2011;38:64-73. https://doi.org/10.1007/s00259-010-1611-1
  77. Graziosi L, Bugiantella W, Cavazzoni E, Cantarella F, Porcari M, Baffa N, et al. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour. Ann Ital Chir 2011;82:125-129.
  78. Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection:comparison of FDG PET/CT and contrast-enhanced abdominal CT. J Korean Med Sci 2011;26:875-880. https://doi.org/10.3346/jkms.2011.26.7.875
  79. Kim SJ, Cho YS, Moon SH, Bae JM, Kim S, Choe YS, et al. Primary tumor 18F-FDG avidity affects the performance of 18F-FDG PET/CT for detecting gastric cancer recurrence. J Nucl Med 2016;57:544-550. https://doi.org/10.2967/jnumed.115.163295
  80. Lee JE, Hong SP, Ahn DH, Jeon TJ, Kang MK, Kwon CI, et al. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy. Yonsei Med J 2011;52:81-88. https://doi.org/10.3349/ymj.2011.52.1.81
  81. Lee DY, Lee CH, Seo MJ, Lee SH, Ryu JS, Lee JJ. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients. Ann Nucl Med 2014;28:789-795. https://doi.org/10.1007/s12149-014-0871-4
  82. Lee JW, Lee SM, Son MW, Lee MS. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection. Eur J Nucl Med Mol Imaging 2016;43:881-888. https://doi.org/10.1007/s00259-015-3249-5
  83. Nakamoto Y, Togashi K, Kaneta T, Fukuda H, Nakajima K, Kitajima K, et al. Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study. Jpn J Clin Oncol 2009;39:297-302. https://doi.org/10.1093/jjco/hyp010
  84. Park MJ, Lee WJ, Lim HK, Park KW, Choi JY, Kim BT. Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging 2009;34:441-447. https://doi.org/10.1007/s00261-008-9424-4
  85. Sharma P, Singh H, Suman SK, Sharma A, Reddy RM, Thulkar S, et al. 18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population. Nucl Med Commun 2012;33:960-966. https://doi.org/10.1097/mnm.0b013e328355b694
  86. Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, et al. The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer 2009;9:73.
  87. Sun L, Su XH, Guan YS, Pan WM, Luo ZM, Wei JH, et al. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results. World J Gastroenterol 2008;14:4627-4632. https://doi.org/10.3748/wjg.14.4627
  88. Kim JH, Heo SH, Kim JW, Shin SS, Min JJ, Kwon SY, et al. Evaluation of recurrence in gastric carcinoma: Comparison of contrast-enhanced computed tomography and positron emission tomography/computed tomography. World J Gastroenterol 2017;23:6448-6456. https://doi.org/10.3748/wjg.v23.i35.6448
  89. National Health Commission of the People's Republic of China. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin J Cancer Res 2022;34:207-237. https://doi.org/10.21147/j.issn.1000-9604.2022.03.04
  90. Reiner-Concin A. External quality assurance in immunohistochemistry - is it the solution to a complex problem? Breast Care (Basel) 2008;3:78-79. https://doi.org/10.1159/000126738
  91. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol 2012;3:251-261. https://doi.org/10.3978/j.issn.2078-6891.2012.021
  92. Agnes A, Estrella JS, Badgwell B. The significance of a nineteenth century definition in the era of genomics: linitis plastica. World J Surg Oncol 2017;15:123.
  93. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182-188. https://doi.org/10.1111/his.13975
  94. International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer; 2019.
  95. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49. https://doi.org/10.1111/apm.1965.64.1.31
  96. Yasuda K, Adachi Y, Shiraishi N, Maeo S, Kitano S. Papillary adenocarcinoma of the stomach. Gastric Cancer 2000;3:33-38. https://doi.org/10.1007/PL00011687
  97. Huang Q, Zou X. Clinicopathology of early gastric carcinoma: an update for pathologists and gastroenterologists. Gastrointest Tumors 2017;3:115-124. https://doi.org/10.1159/000456005
  98. Cheng Y, Du M, Zhou X, Guo L, Xu K, Huang J, et al. High-grade papillary early gastric carcinoma with high risk for lymph node metastasis and poor prognosis: a clinicopathologic study of 96 cases among 1136 consecutive radical gastrectomies. Am J Surg Pathol 2021;45:1661-1668. https://doi.org/10.1097/PAS.0000000000001759
  99. Kim YH, Kim JH, Kim H, Kim H, Lee YC, Lee SK, et al. Is the recent WHO histological classification for gastric cancer helpful for application to endoscopic resection? Gastric Cancer 2016;19:869-875. https://doi.org/10.1007/s10120-015-0538-4
  100. Kook MC. Risk factors for lymph node metastasis in undifferentiated-type gastric carcinoma. Clin Endosc 2019;52:15-20. https://doi.org/10.5946/ce.2018.193
  101. Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Mol Oncol 2021;15:2841-2867. https://doi.org/10.1002/1878-0261.12948
  102. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol 2006;13:836-842. https://doi.org/10.1245/ASO.2006.03.077
  103. Choi JS, Kim MA, Lee HE, Lee HS, Kim WH. Mucinous gastric carcinomas: clinicopathologic and molecular analyses. Cancer 2009;115:3581-3590. https://doi.org/10.1002/cncr.24422
  104. Komatsu S, Ichikawa D, Miyamae M, Shimizu H, Konishi H, Shiozaki A, et al. Histological mixed-type as an independent prognostic factor in stage I gastric carcinoma. World J Gastroenterol 2015;21:549-555. https://doi.org/10.3748/wjg.v21.i2.549
  105. Lee JH, Choi IJ, Han HS, Kim YW, Ryu KW, Yoon HM, et al. Risk of lymph node metastasis in differentiated type mucosal early gastric cancer mixed with minor undifferentiated type histology. Ann Surg Oncol 2015;22:1813-1819. https://doi.org/10.1245/s10434-014-4167-7
  106. Seo HS, Lee GE, Kang MG, Han KH, Jung ES, Song KY. Mixed histology is a risk factor for lymph node metastasis in early gastric cancer. J Surg Res 2019;236:271-277. https://doi.org/10.1016/j.jss.2018.11.055
  107. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21. https://doi.org/10.1007/s10120-020-01042-y
  108. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. AJCC Cancer Staging Manual. Eighth edition. Chicago (IL): Springer; 2017.
  109. Liu YY, Fang WL, Wang F, Hsu JT, Tsai CY, Liu KH, et al. Does a higher cutoff value of lymph node retrieval substantially improve survival in patients with advanced gastric cancer?-time to embrace a new digit. Oncologist 2017;22:97-106. https://doi.org/10.1634/theoncologist.2016-0239
  110. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following longcourse neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47:141-146. https://doi.org/10.1111/j.1365-2559.2005.02176.x
  111. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:167-192. https://doi.org/10.6004/jnccn.2022.0008
  112. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  113. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:446-464. https://doi.org/10.1200/JCO.2016.69.4836
  114. Lee HS, Kim WH, Kwak Y, Koh J, Bae JM, Kim KM, et al. Molecular testing for gastrointestinal cancer. J Pathol Transl Med 2017;51:103-121. https://doi.org/10.4132/jptm.2017.01.24
  115. Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci 2018;75:4151-4162. https://doi.org/10.1007/s00018-018-2906-9
  116. Murphy KM, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 2006;8:305-311. https://doi.org/10.2353/jmoldx.2006.050092
  117. Luchini C, Bibeau F, Ligtenberg MJ, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019;30:1232-1243. https://doi.org/10.1093/annonc/mdz116
  118. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209. https://doi.org/10.1038/nature13480
  119. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 2018;24:1449-1458. https://doi.org/10.1038/s41591-018-0101-z
  120. Yoon CJ, Chang MS, Kim DH, Kim W, Koo BK, Yun SC, et al. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas. Gastric Cancer 2020;23:780-795. https://doi.org/10.1007/s10120-020-01059-3
  121. Lee HS, Chang MS, Yang HK, Lee BL, Kim WH. Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma. Clin Cancer Res 2004;10:1698-1705. https://doi.org/10.1158/1078-0432.ccr-1122-3
  122. Kwak Y, Seo AN, Lee HE, Lee HS. Tumor immune response and immunotherapy in gastric cancer. J Pathol Transl Med 2020;54:20-33. https://doi.org/10.4132/jptm.2019.10.08
  123. DAKO Agilent Technologies. Interpretation Manual: Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 PharmDx Interpretation Manual: Gastric or Gastroesophageal Junction Adenocarcinoma. Santa Clara (CA): DAKO Agilent Technologies; 2018.
  124. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 Clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.
  125. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
  126. Catenacci DV, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, et al. Phase I Escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol 2020;38:2418-2426. https://doi.org/10.1200/JCO.19.01834
  127. Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov 2018;8:696-713. https://doi.org/10.1158/2159-8290.CD-17-1260
  128. Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PG, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 2019;9:1388-1405. https://doi.org/10.1158/2159-8290.cd-19-0442
  129. Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, et al. Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget 2018;9:36654-36665. https://doi.org/10.18632/oncotarget.26336
  130. Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res 2022;28:3489-3498. https://doi.org/10.1158/1078-0432.CCR-22-0121
  131. Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer 2019;7:183.
  132. Ascierto PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N. Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis. J Mol Diagn 2019;21:756-767. https://doi.org/10.1016/j.jmoldx.2019.05.004
  133. Kim WH, Park CK, Kim YB, Kim YW, Kim HG, Bae HI, et al. A standardized pathology report for gastric cancer. Korean J Pathol 2005;39:106-113.
  134. Park YS, Kook MC, Kim BH, Lee HS, Kang DW, Gu MJ, et al. A standardized pathology report for gastric cancer: 2nd edition. J Gastric Cancer 2023;23:107-145. https://doi.org/10.5230/jgc.2023.23.e7
  135. Chung IK, Lee JH, Lee SH, Kim SJ, Cho JY, Cho WY, et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc 2009;69:1228-1235. https://doi.org/10.1016/j.gie.2008.09.027
  136. Kim SG, Lyu DH, Park CM, Lee NR, Kim J, Cha Y, et al. Current status of endoscopic submucosal dissection for early gastric cancer in Korea: role and benefits. Korean J Intern Med 2019;34:785-793. https://doi.org/10.3904/kjim.2017.374
  137. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219-225. https://doi.org/10.1007/PL00011720
  138. Nishizawa T, Yahagi N. Long-term outcomes of using endoscopic submucosal dissection to treat early gastric cancer. Gut Liver 2018;12:119-124. https://doi.org/10.5009/gnl17095
  139. Hahn KY, Park CH, Lee YK, Chung H, Park JC, Shin SK, et al. Comparative study between endoscopic submucosal dissection and surgery in patients with early gastric cancer. Surg Endosc 2018;32:73-86. https://doi.org/10.1007/s00464-017-5640-8
  140. Choi IJ, Lee JH, Kim YI, Kim CG, Cho SJ, Lee JY, et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointest Endosc 2015;81:333-41.e1. https://doi.org/10.1016/j.gie.2014.07.047
  141. Choi KS, Jung HY, Choi KD, Lee GH, Song HJ, Kim DH, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc 2011;73:942-948. https://doi.org/10.1016/j.gie.2010.12.032
  142. Kim DY, Hong SJ, Cho GS, Jeong GA, Kim HK, Han JP, et al. Long-term efficacy of endoscopic submucosal dissection compared with surgery for early gastric cancer: a retrospective cohort study. Gut Liver 2014;8:519-525. https://doi.org/10.5009/gnl13061
  143. Fukase KM, Suzuki M, Toda H, Okuyama Y, Sakai J. Evaluation of the efficacy of endoscopic treatment for gastric cancer considered in terms of long-term prognosis. Dig Endosc 1994;6:241-247. https://doi.org/10.1111/j.1443-1661.1994.tb00373.x
  144. Lee S, Choi KD, Han M, Na HK, Ahn JY, Jung KW, et al. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer meeting expanded indication including undifferentiatedtype tumors: a criteria-based analysis. Gastric Cancer 2018;21:490-499. https://doi.org/10.1007/s10120-017-0772-z
  145. Honda M, Hiki N, Kinoshita T, Yabusaki H, Abe T, Nunobe S, et al. Long-term outcomes of laparoscopic versus open surgery for clinical stage I gastric cancer: the LOC-1 study. Ann Surg 2016;264:214-222. https://doi.org/10.1097/SLA.0000000000001654
  146. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol 2014;32:627-633. https://doi.org/10.1200/JCO.2013.48.8551
  147. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg 2016;263:28-35. https://doi.org/10.1097/SLA.0000000000001346
  148. Lee S, Choi KD, Hong SM, Park SH, Gong EJ, Na HK, et al. Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer:Korean experiences. Gastric Cancer 2017;20:843-852. https://doi.org/10.1007/s10120-017-0691-z
  149. Kim ER, Lee H, Min BH, Lee JH, Rhee PL, Kim JJ, et al. Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. Br J Surg 2015;102:1394-1401. https://doi.org/10.1002/bjs.9873
  150. Oda I, Oyama T, Abe S, Ohnita K, Kosaka T, Hirasawa K, et al. Preliminary results of multicenter questionnaire study on long-term outcomes of curative endoscopic submucosal dissection for early gastric cancer. Dig Endosc 2014;26:214-219. https://doi.org/10.1111/den.12141
  151. Kim HJ, Chung H, Shin SK, Kim HI, Park JC, Lee SK, et al. Comparison of long-term clinical outcomes between endoscopic and surgical resection for early-stage adenocarcinoma of the esophagogastric junction. Surg Endosc 2018;32:3540-3547. https://doi.org/10.1007/s00464-018-6076-5
  152. Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, et al. Comparison of clinical outcomes after endoscopic submucosal dissection and surgery in the treatment of early gastric cancer: a single-institute study. Medicine (Baltimore) 2017;96:e7210.
  153. Chiu PW, Teoh AY, To KF, Wong SK, Liu SY, Lam CC, et al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Surg Endosc 2012;26:3584-3591. https://doi.org/10.1007/s00464-012-2371-8
  154. Cho JH, Cha SW, Kim HG, Lee TH, Cho JY, Ko WJ, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a comparison study to surgery using propensity score-matched analysis. Surg Endosc 2016;30:3762-3773. https://doi.org/10.1007/s00464-015-4672-1
  155. Feng F, Sun L, Xu G, Cai L, Hong L, Yang J, et al. Is it reasonable to treat early gastric cancer with mucosal infiltration and well differentiation by endoscopic submucosal resection? J Gastrointest Surg 2015;19:2111-2119. https://doi.org/10.1007/s11605-015-2932-y
  156. Fukunaga S, Nagami Y, Shiba M, Ominami M, Tanigawa T, Yamagami H, et al. Long-term prognosis of expanded-indication differentiated-type early gastric cancer treated with endoscopic submucosal dissection or surgery using propensity score analysis. Gastrointest Endosc 2017;85:143-152. https://doi.org/10.1016/j.gie.2016.06.049
  157. Gong EJ, Kim DH, Ahn JY, Jung KW, Lee JH, Choi KD, et al. Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. Gastric Cancer 2017;20 Suppl 1:84-91. https://doi.org/10.1007/s10120-016-0679-0
  158. Kim YI, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, et al. Long-term survival after endoscopic resection versus surgery in early gastric cancers. Endoscopy 2015;47:293-301. https://doi.org/10.1055/s-0034-1391284
  159. Park CH, Lee H, Kim DW, Chung H, Park JC, Shin SK, et al. Clinical safety of endoscopic submucosal dissection compared with surgery in elderly patients with early gastric cancer: a propensity-matched analysis. Gastrointest Endosc 2014;80:599-609. https://doi.org/10.1016/j.gie.2014.04.042
  160. Pyo JH, Lee H, Min BH, Lee JH, Choi MG, Lee JH, et al. Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. Am J Gastroenterol 2016;111:240-249. https://doi.org/10.1038/ajg.2015.427
  161. Shin DW, Hwang HY, Jeon SW. Comparison of endoscopic submucosal dissection and surgery for differentiated type early gastric cancer within the expanded criteria. Clin Endosc 2017;50:170-178. https://doi.org/10.5946/ce.2016.017
  162. Eom BW, Kim YI, Kim KH, Yoon HM, Cho SJ, Lee JY, et al. Survival benefit of additional surgery after noncurative endoscopic resection in patients with early gastric cancer. Gastrointest Endosc 2017;85:155-163.e3. https://doi.org/10.1016/j.gie.2016.07.036
  163. Hatta W, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, et al. Is radical surgery necessary in all patients who do not meet the curative criteria for endoscopic submucosal dissection in early gastric cancer? A multi-center retrospective study in Japan. J Gastroenterol 2017;52:175-184. https://doi.org/10.1007/s00535-016-1210-4
  164. Kusano C, Iwasaki M, Kaltenbach T, Conlin A, Oda I, Gotoda T. Should elderly patients undergo additional surgery after non-curative endoscopic resection for early gastric cancer? Long-term comparative outcomes. Am J Gastroenterol 2011;106:1064-1069. https://doi.org/10.1038/ajg.2011.49
  165. Hirasawa T, Gotoda T, Miyata S, Kato Y, Shimoda T, Taniguchi H, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer 2009;12:148-152. https://doi.org/10.1007/s10120-009-0515-x
  166. Chung JW, Jung HY, Choi KD, Song HJ, Lee GH, Jang SJ, et al. Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. J Gastroenterol Hepatol 2011;26:884-887. https://doi.org/10.1111/j.1440-1746.2010.06611.x
  167. Oh SY, Lee KG, Suh YS, Kim MA, Kong SH, Lee HJ, et al. Lymph node metastasis in mucosal gastric cancer:reappraisal of expanded indication of endoscopic submucosal dissection. Ann Surg 2017;265:137-142. https://doi.org/10.1097/SLA.0000000000001649
  168. Abdelfatah MM, Barakat M, Lee H, Kim JJ, Uedo N, Grimm I, et al. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and metaanalysis. Gastrointest Endosc 2018;87:338-347. https://doi.org/10.1016/j.gie.2017.09.025
  169. Huh CW, Ma DW, Kim BW, Kim JS, Lee SJ. Endoscopic submucosal dissection versus surgery for undifferentiated-type early gastric cancer: a systematic review and meta-analysis. Clin Endosc 2021;54:202-210. https://doi.org/10.5946/ce.2020.121
  170. Lee GH, Lee E, Park B, Roh J, Lim SG, Shin SJ, et al. Long-term outcomes of endoscopic submucosal dissection and surgery for undifferentiated intramucosal gastric cancer regardless of size. World J Gastroenterol 2022;28:840-852. https://doi.org/10.3748/wjg.v28.i8.840
  171. Lim JH, Kim J, Kim SG, Chung H. Long-term clinical outcomes of endoscopic vs. surgical resection for early gastric cancer with undifferentiated histology. Surg Endosc 2019;33:3589-3599. https://doi.org/10.1007/s00464-018-06641-6
  172. Takizawa K, Ono H, Hasuike N, Takashima A, Minashi K, Boku N, et al. A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010). Gastric Cancer 2021;24:479-491. https://doi.org/10.1007/s10120-020-01134-9
  173. Choi JY, Jeon SW, Cho KB, Park KS, Kim ES, Park CK, et al. Non-curative endoscopic resection does not always lead to grave outcomes in submucosal invasive early gastric cancer. Surg Endosc 2015;29:1842-1849. https://doi.org/10.1007/s00464-014-3874-2
  174. Hoteya S, Iizuka T, Kikuchi D, Ogawa O, Mitani T, Matsui A, et al. Clinicopathological outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Digestion 2016;93:53-58. https://doi.org/10.1159/000441758
  175. Yamanouchi K, Ogata S, Sakata Y, Tsuruoka N, Shimoda R, Nakayama A, et al. Effect of additional surgery after noncurative endoscopic submucosal dissection for early gastric cancer. Endosc Int Open 2016;4:E24-E29. https://doi.org/10.1055/s-0034-1393124
  176. Kawata N, Kakushima N, Takizawa K, Tanaka M, Makuuchi R, Tokunaga M, et al. Risk factors for lymph node metastasis and long-term outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Surg Endosc 2017;31:1607-1616. https://doi.org/10.1007/s00464-016-5148-7
  177. Kikuchi S, Kuroda S, Nishizaki M, Kagawa T, Kanzaki H, Kawahara Y, et al. Management of early gastric cancer that meet the indication for radical lymph node dissection following endoscopic resection: a retrospective cohort analysis. BMC Surg 2017;17:72.
  178. Pyo JH, Lee H, Min BH, Lee JH, Kim KM, Yoo H, et al. Comparison of long-term outcomes after noncurative endoscopic resection in older patients with early gastric cancer. Ann Surg Oncol 2017;24:2624-2631. https://doi.org/10.1245/s10434-017-5888-1
  179. Sumiyoshi T, Kondo H, Fujii R, Minagawa T, Fujie S, Kimura T, et al. Short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer in elderly patients aged 75 years and older. Gastric Cancer 2017;20:489-495. https://doi.org/10.1007/s10120-016-0628-y
  180. Suzuki S, Gotoda T, Hatta W, Oyama T, Kawata N, Takahashi A, et al. Survival benefit of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer: a propensity score matching analysis. Ann Surg Oncol 2017;24:3353-3360. https://doi.org/10.1245/s10434-017-6039-4
  181. Toya Y, Endo M, Nakamura S, Akasaka R, Kosaka T, Yanai S, et al. Clinical outcomes of non-curative endoscopic submucosal dissection with negative resected margins for gastric cancer. Gastrointest Endosc 2017;85:1218-1224. https://doi.org/10.1016/j.gie.2016.11.018
  182. Jeon MY, Park JC, Hahn KY, Shin SK, Lee SK, Lee YC. Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment. Gastrointest Endosc 2018;87:1003-1013.e2. https://doi.org/10.1016/j.gie.2017.10.004
  183. Yano T, Ishido K, Tanabe S, Wada T, Azuma M, Kawanishi N, et al. Long-term outcomes of patients with early gastric cancer found to have lesions for which endoscopic treatment is not indicated on histopathological evaluation after endoscopic submucosal dissection. Surg Endosc 2018;32:1314-1323. https://doi.org/10.1007/s00464-017-5809-1
  184. Kim HJ, Kim SG, Kim J, Hong H, Lee HJ, Kim MS, et al. Clinical outcomes of early gastric cancer with non-curative resection after pathological evaluation based on the expanded criteria. PLoS One 2019;14:e0224614.
  185. Iwai N, Dohi O, Naito Y, Inada Y, Inoue K, Okayama T, et al. High-risk comorbidity influences prognosis in early gastric cancer after noncurative endoscopic submucosal dissection: a retrospective study. Dig Dis 2021;39:96-105. https://doi.org/10.1159/000510115
  186. Min SH, Son SY, Jung DH, Lee CM, Ahn SH, Park DJ, et al. Laparoscopic gastrojejunostomy versus duodenal stenting in unresectable gastric cancer with gastric outlet obstruction. Ann Surg Treat Res 2017;93:130-136. https://doi.org/10.4174/astr.2017.93.3.130
  187. Sekiguchi M, Suzuki H, Oda I, Abe S, Nonaka S, Yoshinaga S, et al. Risk of recurrent gastric cancer after endoscopic resection with a positive lateral margin. Endoscopy 2014;46:273-278. https://doi.org/10.1055/s-0034-1364938
  188. Hwang JJ, Park KJ, Park YS, Lee HS, Yoon H, Shin CM, et al. A scoring system for patients with a tumor-positive lateral resection margin after endoscopic resection of early gastric cancer. Surg Endosc 2016;30:2751-2758. https://doi.org/10.1007/s00464-015-4543-9
  189. Kikuchi D, Iizuka T, Hoteya S, Yamada A, Furuhata T, Yamashita S, et al. Safety and efficacy of secondary endoscopic submucosal dissection for residual gastric carcinoma after primary endoscopic submucosal dissection. Digestion 2012;86:288-293. https://doi.org/10.1159/000342114
  190. Kim HW, Kim JH, Park JC, Jeon MY, Lee YC, Lee SK, et al. Additive endoscopic resection may be sufficient for patients with a positive lateral margin after endoscopic resection of early gastric cancer. Gastrointest Endosc 2017;86:849-856. https://doi.org/10.1016/j.gie.2017.02.037
  191. Kim TS, Min BH, Min YW, Lee H, Rhee PL, Kim JJ, et al. Long-term outcomes of additional endoscopic treatments for patients with positive lateral margins after endoscopic submucosal dissection for early gastric cancer. Gut Liver 2022;16:547-554. https://doi.org/10.5009/gnl210203
  192. Oda I, Gotoda T, Sasako M, Sano T, Katai H, Fukagawa T, et al. Treatment strategy after non-curative endoscopic resection of early gastric cancer. Br J Surg 2008;95:1495-1500. https://doi.org/10.1002/bjs.6305
  193. Lee JH, Lee JH, Kim KM, Kang KJ, Min BH, Kim JJ. Clinicopathological factors of multiple lateral margin involvement after endoscopic submucosal dissection for early gastric cancer. Surg Endosc 2015;29:3460-3468. https://doi.org/10.1007/s00464-015-4095-z
  194. Yang HJ, Lee WS, Lee BE, Ahn JY, Jang JY, Lim JH, et al. Long-term outcomes of undifferentiated-type early gastric cancer with positive horizontal margins after endoscopic resection. Gut Liver 2021;15:723-731. https://doi.org/10.5009/gnl20291
  195. Ahn S, Do IG, Sohn JH, Yang HJ, Yoo CH, Kim K. Total length of positive resection margins can predict remnant gastric cancer following endoscopic submucosal dissection. Pathol Res Pract 2020;216:153183.
  196. Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020;7:CD005583.
  197. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer:an open-label, randomised controlled trial. Lancet 2008;372:392-397. https://doi.org/10.1016/S0140-6736(08)61159-9
  198. Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095. https://doi.org/10.1056/NEJMoa1708423
  199. Smith JW, Brennan MF. Surgical treatment of gastric cancer. Proximal, mid, and distal stomach. Surg Clin North Am 1992;72:381-399. https://doi.org/10.1016/s0039-6109(16)45685-9
  200. Lee MS, Ahn SH, Lee JH, Park DJ, Lee HJ, Kim HH, et al. What is the best reconstruction method after distal gastrectomy for gastric cancer? Surg Endosc 2012;26:1539-1547. https://doi.org/10.1007/s00464-011-2064-8
  201. Ren Z, Wang WX. Comparison of Billroth I, Billroth II, and Roux-en-Y reconstruction after totally laparoscopic distal gastrectomy: a randomized controlled study. Adv Ther 2019;36:2997-3006. https://doi.org/10.1007/s12325-019-01104-3
  202. Ishikawa M, Kitayama J, Kaizaki S, Nakayama H, Ishigami H, Fujii S, et al. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. World J Surg 2005;29:1415-1420. https://doi.org/10.1007/s00268-005-7830-0
  203. Hirao M, Takiguchi S, Imamura H, Yamamoto K, Kurokawa Y, Fujita J, et al. Comparison of Billroth I and Roux-en-Y reconstruction after distal gastrectomy for gastric cancer: one-year postoperative effects assessed by a multi-institutional RCT. Ann Surg Oncol 2013;20:1591-1597. https://doi.org/10.1245/s10434-012-2704-9
  204. Nakamura M, Nakamori M, Ojima T, Iwahashi M, Horiuchi T, Kobayashi Y, et al. Randomized clinical trial comparing long-term quality of life for Billroth I versus Roux-en-Y reconstruction after distal gastrectomy for gastric cancer. Br J Surg 2016;103:337-347. https://doi.org/10.1002/bjs.10060
  205. Yang K, Zhang WH, Liu K, Chen XZ, Zhou ZG, Hu JK. Comparison of quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial. Sci Rep 2017;7:11245.
  206. Kim SY, Bang WJ, Lim H, Lim MS, Kim M, Choi HG. Increased risk of gallstones after gastrectomy:a longitudinal follow-up study using a national sample cohort in Korea. Medicine (Baltimore) 2019;98:e15932.
  207. Park DJ, Kim KH, Park YS, Ahn SH, Park J, Kim HH. Risk factors for gallstone formation after surgery for gastric cancer. J Gastric Cancer 2016;16:98-104. https://doi.org/10.5230/jgc.2016.16.2.98
  208. Kim JH, Huh YJ, Park S, Park YS, Park DJ, Kwon JW, et al. Multicenter results of long-limb bypass reconstruction after gastrectomy in patients with gastric cancer and type II diabetes. Asian J Surg 2020;43:297-303. https://doi.org/10.1016/j.asjsur.2019.03.018
  209. Toyomasu Y, Ogata K, Suzuki M, Yanoma T, Kimura A, Kogure N, et al. Comparison of the physiological effect of Billroth-I and Roux-en-Y reconstruction following laparoscopic distal gastrectomy. Surg Laparosc Endosc Percutan Tech 2018;28:328-333. https://doi.org/10.1097/SLE.0000000000000575
  210. So JB, Rao J, Wong AS, Chan YH, Pang NQ, Tay AY, et al. Roux-en-Y or Billroth II reconstruction after radical distal gastrectomy for gastric cancer: a multicenter randomized controlled trial. Ann Surg 2018;267:236-242. https://doi.org/10.1097/SLA.0000000000002229
  211. Choi YS, Yi JW, Shin WY, Heo Y. Oncometabolic surgery in gastric cancer patients with type 2 diabetes. Sci Rep 2022;12:11853.
  212. Inokuchi M, Kojima K, Yamada H, Kato K, Hayashi M, Motoyama K, et al. Long-term outcomes of Rouxen-Y and Billroth-I reconstruction after laparoscopic distal gastrectomy. Gastric Cancer 2013;16:67-73. https://doi.org/10.1007/s10120-012-0154-5
  213. Tanigawa N, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, et al. Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. World J Surg 2010;34:1540-1547. https://doi.org/10.1007/s00268-010-0505-5
  214. Shin D, Park SS. Clinical importance and surgical decision-making regarding proximal resection margin for gastric cancer. World J Gastrointest Oncol 2013;5:4-11. https://doi.org/10.4251/wjgo.v5.i1.4
  215. Sun Z, Li DM, Wang ZN, Huang BJ, Xu Y, Li K, et al. Prognostic significance of microscopic positive margins for gastric cancer patients with potentially curative resection. Ann Surg Oncol 2009;16:3028-3037. https://doi.org/10.1245/s10434-009-0624-0
  216. Nagata T, Ichikawa D, Komatsu S, Inoue K, Shiozaki A, Fujiwara H, et al. Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol 2011;104:592-597. https://doi.org/10.1002/jso.22022
  217. Morgagni P, La Barba G, Colciago E, Vittimberga G, Ercolani G. Resection line involvement after gastric cancer treatment: handle with care. Updates Surg 2018;70:213-223. https://doi.org/10.1007/s13304-018-0552-2
  218. Morgagni P, Garcea D, Marrelli D, De Manzoni G, Natalini G, Kurihara H, et al. Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. World J Surg 2008;32:2661-2667. https://doi.org/10.1007/s00268-008-9747-x
  219. Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, et al. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg Oncol 2007;95:461-468. https://doi.org/10.1002/jso.20731
  220. Lee CM, Jee YS, Lee JH, Son SY, Ahn SH, Park DJ, et al. Length of negative resection margin does not affect local recurrence and survival in the patients with gastric cancer. World J Gastroenterol 2014;20:10518-10524. https://doi.org/10.3748/wjg.v20.i30.10518
  221. Cascinu S, Giordani P, Catalano V, Agostinelli R, Catalano G. Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. Jpn J Clin Oncol 1999;29:291-293. https://doi.org/10.1093/jjco/29.6.291
  222. Raziee HR, Cardoso R, Seevaratnam R, Mahar A, Helyer L, Law C, et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer 2012;15 Suppl 1:S116-S124. https://doi.org/10.1007/s10120-011-0112-7
  223. Park SH, Lee HJ, Park JH, Kim TH, Son YG, Huh YJ, et al. Clinical significance of intra-operative gastroscopy for tumor localization in totally laparoscopic partial gastrectomy. J Gastrointest Surg 2021;25:1134-1146. https://doi.org/10.1007/s11605-020-04809-x
  224. Choi Y, Kim KG, Kim JK, Nam KW, Kim HH, Sohn DK. A novel endoscopic fluorescent clip for the localization of gastrointestinal tumors. Surg Endosc 2011;25:2372-2377. https://doi.org/10.1007/s00464-010-1557-1
  225. Jeong O, Cho SB, Joo YE, Ryu SY, Park YK. Novel technique for intraoperative tumor localization during totally laparoscopic distal gastrectomy: endoscopic autologous blood tattooing. Surg Endosc 2012;26:1778-1783. https://doi.org/10.1007/s00464-011-2067-5
  226. Jeong SH, Bae K, Ha CY, Lee YJ, Lee OJ, Jung WT, et al. Effectiveness of endoscopic clipping and computed tomography gastroscopy for the preoperative localization of gastric cancer. J Korean Surg Soc 2013;84:80-87. https://doi.org/10.4174/jkss.2013.84.2.80
  227. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH. Intraoperative frozen section margin evaluation in gastric cancer of the cardia surgery. Hepatogastroenterology 2006;53:976-978.
  228. Hyung WJ, Lim JS, Cheong JH, Kim J, Choi SH, Song SY, et al. Intraoperative tumor localization using laparoscopic ultrasonography in laparoscopic-assisted gastrectomy. Surg Endosc 2005;19:1353-1357. https://doi.org/10.1007/s00464-004-8196-3
  229. Park DJ, Lee HJ, Kim SG, Jung HC, Song IS, Lee KU, et al. Intraoperative gastroscopy for gastric surgery. Surg Endosc 2005;19:1358-1361. https://doi.org/10.1007/s00464-004-2217-0
  230. Berlth F, Kim WH, Choi JH, Park SH, Kong SH, Lee HJ, et al. Prognostic impact of frozen section investigation and extent of proximal safety margin in gastric cancer resection. Ann Surg 2020;272:871-878. https://doi.org/10.1097/SLA.0000000000004266
  231. Park JH, Jeong SH, Lee YJ, Kim TH, Kim JM, Kim DH, et al. Safety and efficacy of post-anastomotic intraoperative endoscopy to avoid early anastomotic complications during gastrectomy for gastric cancer. Surg Endosc 2020;34:5312-5319. https://doi.org/10.1007/s00464-019-07319-3
  232. Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol 2009;16:2738-2743. https://doi.org/10.1245/s10434-009-0616-0
  233. Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persano S, Andreola S, et al. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 1982;196:685-690. https://doi.org/10.1097/00000658-198212001-00012
  234. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer 2023;26:1-25. https://doi.org/10.1007/s10120-022-01331-8
  235. Squires MH 3rd, Kooby DA, Pawlik TM, Weber SM, Poultsides G, Schmidt C, et al. Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: a 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg Oncol 2014;21:4202-4210. https://doi.org/10.1245/s10434-014-3834-z
  236. Nakanishi K, Morita S, Taniguchi H, Otsuki S, Fukagawa T, Katai H. Diagnostic accuracy and usefulness of intraoperative margin assessment by frozen section in gastric cancer. Ann Surg Oncol 2019;26:1787-1794. https://doi.org/10.1245/s10434-019-07302-1
  237. Spicer J, Benay C, Lee L, Rousseau M, Andalib A, Kushner Y, et al. Diagnostic accuracy and utility of intraoperative microscopic margin analysis of gastric and esophageal adenocarcinoma. Ann Surg Oncol 2014;21:2580-2586. https://doi.org/10.1245/s10434-014-3669-7
  238. Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg 1999;3:24-33. https://doi.org/10.1016/S1091-255X(99)80004-3
  239. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH. Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol 2006;12:3883-3886. https://doi.org/10.3748/wjg.v12.i24.3883
  240. Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol 2013;20:2663-2668. https://doi.org/10.1245/s10434-013-2950-5
  241. Liang Y, Ding X, Wang X, Wang B, Deng J, Zhang L, et al. Prognostic value of surgical margin status in gastric cancer patients. ANZ J Surg 2015;85:678-684. https://doi.org/10.1111/ans.12515
  242. Chen JD, Yang XP, Shen JG, Hu WX, Yuan XM, Wang LB. Prognostic improvement of reexcision for positive resection margins in patients with advanced gastric cancer. Eur J Surg Oncol 2013;39:229-234. https://doi.org/10.1016/j.ejso.2012.08.004
  243. Lee S, Son WJ, Roh YH, Song JH, Park SH, Cho M, et al. Indication of proximal gastrectomy for advanced proximal gastric cancer based on lymph node metastasis at the distal part of the stomach. Ann Surg Open 2021;2:e107.
  244. Kong SH, Kim JW, Lee HJ, Kim WH, Lee KU, Yang HK. Reverse double-stapling end-to-end esophagogastrostomy in proximal gastrectomy. Dig Surg 2010;27:170-174. https://doi.org/10.1159/000264658
  245. Cho M, Son T, Kim HI, Noh SH, Choi S, Seo WJ, et al. Similar hematologic and nutritional outcomes after proximal gastrectomy with double-tract reconstruction in comparison to total gastrectomy for early upper gastric cancer. Surg Endosc 2019;33:1757-1768. https://doi.org/10.1007/s00464-018-6448-x
  246. Jung DH, Lee Y, Kim DW, Park YS, Ahn SH, Park DJ, et al. Laparoscopic proximal gastrectomy with double tract reconstruction is superior to laparoscopic total gastrectomy for proximal early gastric cancer. Surg Endosc 2017;31:3961-3969. https://doi.org/10.1007/s00464-017-5429-9
  247. Sugiyama M, Oki E, Ando K, Nakashima Y, Saeki H, Maehara Y. Laparoscopic proximal gastrectomy maintains body weight and skeletal muscle better than total gastrectomy. World J Surg 2018;42:3270-3276. https://doi.org/10.1007/s00268-018-4625-7
  248. Park JY, Park KB, Kwon OK, Yu W. Comparison of laparoscopic proximal gastrectomy with double-tract reconstruction and laparoscopic total gastrectomy in terms of nutritional status or quality of life in early gastric cancer patients. Eur J Surg Oncol 2018;44:1963-1970. https://doi.org/10.1016/j.ejso.2018.08.014
  249. Kim DJ, Kim W. Laparoscopy-assisted proximal gastrectomy with double tract anastomosis is beneficial for vitamin B12 and iron absorption. Anticancer Res 2016;36:4753-4758. https://doi.org/10.21873/anticanres.11031
  250. Ko HJ, Kim KH, Lee SH, Choi CW, Kim SJ, In Choi C, et al. Can proximal gastrectomy with double-tract reconstruction replace total gastrectomy? A propensity score matching analysis. J Gastrointest Surg 2020;24:516-524. https://doi.org/10.1007/s11605-019-04195-z
  251. Park DJ, Han SU, Hyung WJ, et al. Effect of laparoscopic proximal gastrectomy and double-tract reconstruction vs total gastrectomy on hemoglobin level and vitamin B12 supplementation in upper-third early gastric cancer: a KLASS 05 randomized clinical trial. JAMA Netw Open 2023;6:e2256004.
  252. Hayami M, Hiki N, Nunobe S, Mine S, Ohashi M, Kumagai K, et al. Clinical outcomes and evaluation of laparoscopic proximal gastrectomy with double-flap technique for early gastric cancer in the upper third of the stomach. Ann Surg Oncol 2017;24:1635-1642. https://doi.org/10.1245/s10434-017-5782-x
  253. Shoji Y, Nunobe S, Ida S, Kumagai K, Ohashi M, Sano T, et al. Surgical outcomes and risk assessment for anastomotic complications after laparoscopic proximal gastrectomy with double-flap technique for upper-third gastric cancer. Gastric Cancer 2019;22:1036-1043. https://doi.org/10.1007/s10120-019-00940-0
  254. Yamashita Y, Yamamoto A, Tamamori Y, Yoshii M, Nishiguchi Y. Side overlap esophagogastrostomy to prevent reflux after proximal gastrectomy. Gastric Cancer 2017;20:728-735. https://doi.org/10.1007/s10120-016-0674-5
  255. Yamashita Y, Tatsubayashi T, Okumura K, Miyamoto T, Ueno K. Modified side overlap esophagogastrostomy after laparoscopic proximal gastrectomy. Ann Gastroenterol Surg 2022;6:594-599. https://doi.org/10.1002/ags3.12549
  256. Lee HJ, Kim YW, Park DJ, Han SU, Ryu KW, Kim HH, et al. Laparoscopic PPG versus DG for middle third EGC; final result of multicenter RCT (KLASS-04). International Gastric Cancer Congress 2022; 2022 Mar 6-9; Houston (TX). Tokyo: International Gastric Cancer Association; 2022.
  257. Park DJ, Kim YW, Yang HK, Ryu KW, Han SU, Kim HH, et al. Short-term outcomes of a multicentre randomized clinical trial comparing laparoscopic pylorus-preserving gastrectomy with laparoscopic distal gastrectomy for gastric cancer (the KLASS-04 trial). Br J Surg 2021;108:1043-1049. https://doi.org/10.1093/bjs/znab295
  258. Suh YS, Han DS, Kong SH, Kwon S, Shin CI, Kim WH, et al. Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 2014;259:485-493. https://doi.org/10.1097/sla.0b013e318294d142
  259. Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukuda K, et al. Evaluation of a pyloruspreserving gastrectomy for patients preoperatively diagnosed with early gastric cancer located in the middle third of the stomach. Surg Today 2010;40:228-233. https://doi.org/10.1007/s00595-009-4043-4
  260. Xiao XM, Gaol C, Yin W, Yu WH, Qi F, Liu T. Pylorus-preserving versus distal subtotal gastrectomy for surgical treatment of early gastric cancer: a meta-analysis. Hepatogastroenterology 2014;61:870-879.
  261. Xia X, Xu J, Zhu C, Cao H, Yu F, Zhao G. Objective evaluation of clinical outcomes of laparoscopy-assisted pylorus-preserving gastrectomy for middle-third early gastric cancer. BMC Cancer 2019;19:481.
  262. Eom BW, Park B, Yoon HM, Ryu KW, Kim YW. Laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer: a retrospective study of long-term functional outcomes and quality of life. World J Gastroenterol 2019;25:5494-5504. https://doi.org/10.3748/wjg.v25.i36.5494
  263. Nakane Y, Akehira K, Inoue K, Iiyama H, Sato M, Masuya Y, et al. Postoperative evaluation of pyloruspreserving gastrectomy for early gastric cancer. Hepatogastroenterology 2000;47:590-595.
  264. Huang C, Yu F, Zhao G, Xia X. Postoperative quality of life after laparoscopy-assisted pylorus-preserving gastrectomy compared with laparoscopy-assisted distal gastrectomy for early gastric cancer. J Gastroenterol Hepatol 2020;35:1712-1719. https://doi.org/10.1111/jgh.14985
  265. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-407. https://doi.org/10.1067/msy.2002.121891
  266. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563. https://doi.org/10.1002/bjs.5353
  267. Hayashi T, Yoshikawa T, Kamiya A, Date K, Wada T, Otsuki S, et al. Is splenectomy for dissecting splenic hilar lymph nodes justified for scirrhous gastric cancer? Gastric Cancer 2020;23:922-926. https://doi.org/10.1007/s10120-020-01063-7
  268. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351. https://doi.org/10.1002/bjs.1800820321
  269. Kosuga T, Ichikawa D, Okamoto K, Komatsu S, Shiozaki A, Fujiwara H, et al. Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients. Gastric Cancer 2011;14:172-177. https://doi.org/10.1007/s10120-011-0028-2
  270. Zheng C, Xu Y, Zhao G, Cai L, Li G, Xu Z, et al. Outcomes of laparoscopic total gastrectomy combined with spleen-preserving hilar lymphadenectomy for locally advanced proximal gastric cancer: a nonrandomized clinical trial. JAMA Netw Open 2021;4:e2139992.
  271. Zheng CH, Xu YC, Zhao G, Cai LS, Li GX, Xu ZK, et al. Safety and feasibility of laparoscopic spleenpreserving No. 10 lymph node dissection for locally advanced upper third gastric cancer: a prospective, multicenter clinical trial. Surg Endosc 2020;34:5062-5073. https://doi.org/10.1007/s00464-019-07306-8
  272. Jeong O, Kim HG, Ryu SY, Park YK, Jung MR. Adverse prognostic impact of splenectomy on survival in gastric carcinoma patients: regression and propensity score matching analysis of 1074 patients. PLoS One 2018;13:e0203820.
  273. Yun WG, Lim MH, Kim S, Kim SH, Park JH, Kong SH, et al. Oncologic feasibility of proximal gastrectomy in upper third advanced gastric and esophagogastric junctional cancer. J Gastric Cancer 2021;21:169-178. https://doi.org/10.5230/jgc.2021.21.e15
  274. Yura M, Yoshikawa T, Otsuki S, Yamagata Y, Morita S, Katai H, et al. Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer. Gastric Cancer 2019;22:1029-1035. https://doi.org/10.1007/s10120-019-00938-8
  275. Isozaki H, Okajima K, Yamada S, Nakata E, Nishimura J, Ichinona T, et al. Proximal subtotal gastrectomy for the treatment of carcinoma of the upper third of the stomach: its indications based on lymph node metastasis and perigastric lymphatic flow. Surg Today 1995;25:21-26. https://doi.org/10.1007/BF00309380
  276. Yang X, Zheng Y, Feng R, Zhu Z, Yan M, Li C. Feasibility of preserving No. 5 and No. 6 lymph nodes in gastrectomy of proximal gastric adenocarcinoma: a retrospective analysis of 395 patients. Front Oncol 2022;12:810509.
  277. Haruta S, Shinohara H, Hosogi H, Ohkura Y, Kobayashi N, Mizuno A, et al. Proximal gastrectomy with exclusion of no. 3b lesser curvature lymph node dissection could be indicated for patients with advanced upper-third gastric cancer. Gastric Cancer 2017;20:528-535. https://doi.org/10.1007/s10120-016-0624-2
  278. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457-1459. https://doi.org/10.1046/j.1365-2168.1998.00940.x
  279. Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 2011;12:296-305. https://doi.org/10.1016/S1470-2045(10)70125-X
  280. Suh YS, Han DS, Kong SH, Lee HJ, Kim YT, Kim WH, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg 2012;255:908-915. https://doi.org/10.1097/SLA.0b013e31824beb95
  281. Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World J Surg Oncol 2017;15:28.
  282. Suh YS, Lee KG, Oh SY, Kong SH, Lee HJ, Kim WH, et al. Recurrence pattern and lymph node metastasis of adenocarcinoma at the esophagogastric junction. Ann Surg Oncol 2017;24:3631-3639. https://doi.org/10.1245/s10434-017-6011-3
  283. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus:five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000. https://doi.org/10.1097/SLA.0b013e31815c4037
  284. Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 2015;102:341-348. https://doi.org/10.1002/bjs.9764
  285. Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, et al. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer 2018;21:303-314. https://doi.org/10.1007/s10120-017-0746-1
  286. Mertens AC, Kalff MC, Eshuis WJ, Van Gulik TM, Van Berge Henegouwen MI, Gisbertz SS, et al. Transthoracic versus transhiatal esophagectomy for esophageal cancer: a nationwide propensity scorematched cohort analysis. Ann Surg Oncol 2021;28:175-183. https://doi.org/10.1245/s10434-020-08760-8
  287. Reddavid R, Strignano P, Sofia S, Evangelista A, Deiro G, Cannata G, et al. Transhiatal distal esophagectomy for Siewert type II cardia cancer can be a treatment option in selected patients. Eur J Surg Oncol 2019;45:1943-1949. https://doi.org/10.1016/j.ejso.2019.04.001
  288. Tosolini C, Reim D, Schirren R, Feith M, Friess H, Novotny AR. Influence of the surgical technique on survival in the treatment of carcinomas of the true cardia (Siewert Type II) - right thoracoabdominal vs. transhiatal-abdominal approach. Eur J Surg Oncol 2019;45:416-424. https://doi.org/10.1016/j.ejso.2018.09.017
  289. Voron T, Gronnier C, Pasquer A, Thereaux J, Gagniere J, Lebreton G, et al. Adenocarcinoma of the oesophagogastric junction Siewert II: an oesophageal cancer better cured with total gastrectomy. Eur J Surg Oncol 2019;45:2473-2481. https://doi.org/10.1016/j.ejso.2019.07.022
  290. Yang ZF, Wu DQ, Wang JJ, Feng XY, Zheng JB, Hu WX, et al. Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal?-a single-center retrospective study. Ann Transl Med 2018;6:6.
  291. Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg 2014;101:511-517. https://doi.org/10.1002/bjs.9456
  292. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  293. Yoo MW, Park DJ, Ahn HS, Jeong SH, Lee HJ, Kim WH, et al. Evaluation of the adequacy of lymph node dissection in pylorus-preserving gastrectomy for early gastric cancer using the maruyama index. World J Surg 2010;34:291-295. https://doi.org/10.1007/s00268-009-0318-6
  294. Kong SH, Yoo MW, Kim JW, Lee HJ, Kim WH, Lee KU, et al. Validation of limited lymphadenectomy for lower-third gastric cancer based on depth of tumour invasion. Br J Surg 2011;98:65-72. https://doi.org/10.1002/bjs.7266
  295. Folli S, Morgagni P, Roviello F, De Manzoni G, Marrelli D, Saragoni L, et al. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 2001;31:495-499. https://doi.org/10.1093/jjco/hye107
  296. Degiuli M, Calvo F. Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg 2006;30:2193-2203. https://doi.org/10.1007/s00268-006-0179-1
  297. Shimoyama S, Yasuda H, Mafune K, Kaminishi M. Indications of a minimized scope of lymphadenectomy for submucosal gastric cancer. Ann Surg Oncol 2002;9:625-631. https://doi.org/10.1007/BF02574477
  298. Kim HH, Han SU, Kim MC, Kim W, Lee HJ, Ryu SW, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial. JAMA Oncol 2019;5:506-513. https://doi.org/10.1001/jamaoncol.2018.6727
  299. Katai H, Mizusawa J, Katayama H, Morita S, Yamada T, Bando E, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2020;5:142-151. https://doi.org/10.1016/S2468-1253(19)30332-2
  300. Kim YW, Yoon HM, Yun YH, Nam BH, Eom BW, Baik YH, et al. Long-term outcomes of laparoscopyassisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301). Surg Endosc 2013;27:4267-4276. https://doi.org/10.1007/s00464-013-3037-x
  301. Wang Z, Dong ZY, Chen JQ, Liu JL. Diagnostic value of sentinel lymph node biopsy in gastric cancer: a meta-analysis. Ann Surg Oncol 2012;19:1541-1550. https://doi.org/10.1245/s10434-011-2124-2
  302. Huang L, Wei T, Chen J, Zhou D. Feasibility and diagnostic performance of dual-tracer-guided sentinel lymph node biopsy in cT1-2N0M0 gastric cancer: a systematic review and meta-analysis of diagnostic studies. World J Surg Oncol 2017;15:103.
  303. Yaguchi Y, Tsujimoto H, Kumano I, Takahata R, Matsumoto Y, Yoshida K, et al. Sentinel node navigation surgery attenuates the functional disorders in early gastric cancer. Oncol Rep 2012;27:643-649. https://doi.org/10.3892/or.2011.1568
  304. Liu N, Niu Z, Niu W, Peng C, Zou X, Sun S, et al. Intraoperative sentinel lymph node mapping guides laparoscopic-assisted distal gastrectomy for distal gastric cancer. Int J Clin Exp Med 2015;8:5760-5766.
  305. Okubo K, Arigami T, Matsushita D, Sasaki K, Kijima T, Noda M, et al. Evaluation of postoperative quality of life by PGSAS-45 following local gastrectomy based on the sentinel lymph node concept in early gastric cancer. Gastric Cancer 2020;23:746-753. https://doi.org/10.1007/s10120-020-01047-7
  306. Youn SI, Son SY, Lee K, Won Y, Min S, Park YS, et al. Quality of life after laparoscopic sentinel node navigation surgery in early gastric cancer: a single-center cohort study. Gastric Cancer 2021;24:744-751. https://doi.org/10.1007/s10120-020-01145-6
  307. Kinami S, Nakamura N, Miyashita T, Kitakata H, Fushida S, Fujimura T, et al. Life prognosis of sentinel node navigation surgery for early-stage gastric cancer: Outcome of lymphatic basin dissection. World J Gastroenterol 2021;27:8010-8030. https://doi.org/10.3748/wjg.v27.i46.8010
  308. Kim YW, Min JS, Yoon HM, An JY, Eom BW, Hur H, et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: a randomized clinical trial. J Clin Oncol 2022;40:2342-2351. https://doi.org/10.1200/JCO.21.02242
  309. Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002;131 Suppl:S306-S311. https://doi.org/10.1067/msy.2002.120115
  310. Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008;248:721-727. https://doi.org/10.1097/SLA.0b013e318185e62e
  311. Katai H, Mizusawa J, Katayama H, Takagi M, Yoshikawa T, Fukagawa T, et al. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer 2017;20:699-708. https://doi.org/10.1007/s10120-016-0646-9
  312. Lee HJ, Hyung WJ, Yang HK, Han SU, Park YK, An JY, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Ann Surg 2019;270:983-991. https://doi.org/10.1097/SLA.0000000000003217
  313. Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 2016;34:1350-1357. https://doi.org/10.1200/JCO.2015.63.7215
  314. Hyung WJ, Yang HK, Park YK, Lee HJ, An JY, Kim W, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial. J Clin Oncol 2020;38:3304-3313. https://doi.org/10.1200/jco.20.01210
  315. Son SY, Hur H, Hyung WJ, Park YK, Lee HJ, An JY, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg 2022;157:879-886. https://doi.org/10.1001/jamasurg.2022.2749
  316. Huang C, Liu H, Hu Y, Sun Y, Su X, Cao H, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial. JAMA Surg 2022;157:9-17. https://doi.org/10.1001/jamasurg.2021.5104
  317. Han SU, Hur H, Lee HJ, Cho GS, Kim MC, Park YK, et al. Surgeon quality control and standardization of D2 lymphadenectomy for gastric cancer: a prospective multicenter observational study (KLASS-02-QC). Ann Surg 2021;273:315-324. https://doi.org/10.1097/SLA.0000000000003883
  318. Lee S, Kim JK, Kim YN, Jang DS, Kim YM, Son T, et al. Safety and feasibility of reduced-port robotic distal gastrectomy for gastric cancer: a phase I/II clinical trial. Surg Endosc 2017;31:4002-4009. https://doi.org/10.1007/s00464-017-5435-y
  319. Eom BW, Yoon HM, Ryu KW, Lee JH, Cho SJ, Lee JY, et al. Comparison of surgical performance and shortterm clinical outcomes between laparoscopic and robotic surgery in distal gastric cancer. Eur J Surg Oncol 2012;38:57-63. https://doi.org/10.1016/j.ejso.2011.09.006
  320. Lu J, Zheng CH, Xu BB, Xie JW, Wang JB, Lin JX, et al. Assessment of robotic versus laparoscopic distal gastrectomy for gastric cancer: a randomized controlled trial. Ann Surg 2021;273:858-867. https://doi.org/10.1097/SLA.0000000000004466
  321. Kim DJ, Lee JH, Kim W. A comparison of total versus partial omentectomy for advanced gastric cancer in laparoscopic gastrectomy. World J Surg Oncol 2014;12:64.
  322. Hasegawa S, Kunisaki C, Ono H, Oshima T, Fujii S, Taguri M, et al. Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study. Gastric Cancer 2013;16:383-388. https://doi.org/10.1007/s10120-012-0198-6
  323. Lee S, Suh YS, Kang SH, Won Y, Park YS, Ahn SH, et al. Should total omentectomy be performed for advanced gastric cancer?: The role of omentectomy during laparoscopic gastrectomy for advanced gastric cancer. Surg Endosc 2022;36:6937-6948. https://doi.org/10.1007/s00464-022-09039-7
  324. Ri M, Nunobe S, Honda M, Akimoto E, Kinoshita T, Hori S, et al. Gastrectomy with or without omentectomy for cT3-4 gastric cancer: a multicentre cohort study. Br J Surg 2020;107:1640-1647. https://doi.org/10.1002/bjs.11702
  325. Seo WJ, Choi S, Roh CK, Cho M, Kim YM, Kim HI, et al. Omentum preservation as an oncologically comparable and surgically superior alternative to total omentectomy during radical gastrectomy for T3-T4 gastric cancer. Surgery 2021;170:610-616. https://doi.org/10.1016/j.surg.2021.02.008
  326. Chai SW, Wang SH, Wang CY, Chen YC, Soong RS, Huang TS. Partial versus total omentectomy in patients with gastric cancer: a systemic review and meta-analysis. Cancers (Basel) 2021;13:13.
  327. Ishizuka M, Shibuya N, Takagi K, Hachiya H, Tago K, Matsumoto T, et al. Omentectomy does not affect the postoperative outcome of patients with locally advanced gastric cancer: a systematic review and metaanalysis. J Surg Res 2021;264:287-295. https://doi.org/10.1016/j.jss.2021.02.033
  328. Kong M, Chen H, Zhang R, Sheng H, Li L. Overall survival advantage of omentum preservation over omentectomy for advanced gastric cancer: a systematic review and meta-analysis. World J Surg 2022;46:1952-1961. https://doi.org/10.1007/s00268-022-06562-5
  329. Lin HW, Loh EW, Shen SC, Tam KW. Gastrectomy with or without omentectomy for gastric cancer: a systematic review and meta-analysis. Surgery 2022;171:1281-1289. https://doi.org/10.1016/j.surg.2021.10.052
  330. Zhu A, Yin G, Liu X, Kong W, Zhang Y, Shan Y, et al. Efficiency of complete omentectomy in patients with resectable gastric cancer: a meta-analysis and systematic review. BMC Gastroenterol 2021;21:346.
  331. Wang CJ, Kong SH, Park JH, Choi JH, Park SH, Zhu CC, et al. Preservation of hepatic branch of the vagus nerve reduces the risk of gallstone formation after gastrectomy. Gastric Cancer 2021;24:232-244. https://doi.org/10.1007/s10120-020-01106-z
  332. Lee YW, Kim A, Han M, Yoo MW. Risk factors for gallbladder stone formation after gastric cancer surgery. J Gastric Cancer 2019;19:417-426. https://doi.org/10.5230/jgc.2019.19.e37
  333. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;27:153-158. https://doi.org/10.1007/s00268-002-6279-7
  334. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-816. https://doi.org/10.1097/01.sla.0000143245.28656.15
  335. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  336. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  337. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer 1998;1:10-24. https://doi.org/10.1007/PL00011681
  338. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th ed. Chicago (IL): Springer; 2002.
  339. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
  340. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  341. Lee KG, Lee HJ, Oh SY, Yang JY, Ahn HS, Suh YS, et al. Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer patients in stage II in the 7th TNM but stage I in the 6th TNM system? Ann Surg Oncol 2016;23:1234-1243. https://doi.org/10.1245/s10434-015-4980-7
  342. Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 2019;4:208-216. https://doi.org/10.1016/S2468-1253(18)30383-2
  343. Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer 2022;25:188-196. https://doi.org/10.1007/s10120-021-01224-2
  344. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. Chicago (IL): Springer; 2010.
  345. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021;32:368-374. https://doi.org/10.1016/j.annonc.2020.11.017
  346. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017;8:CD004064.
  347. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. https://doi.org/10.1056/NEJMoa073149
  348. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673. https://doi.org/10.1093/annonc/mdn717
  349. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracilbased combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-1534. https://doi.org/10.1093/annonc/mdp047
  350. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-1069. https://doi.org/10.1016/S1470-2045(09)70259-1
  351. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-1553. https://doi.org/10.1200/JCO.2009.25.4706
  352. Kang YK, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21:1045-1056. https://doi.org/10.1016/s1470-2045(20)30315-6
  353. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442. https://doi.org/10.1200/JCO.2007.13.9378
  354. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 2015;26:141-148. https://doi.org/10.1093/annonc/mdu472
  355. Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, et al. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer 2021;24:156-167. https://doi.org/10.1007/s10120-020-01101-4
  356. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997. https://doi.org/10.1200/JCO.2006.06.8429
  357. Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4:501-510. https://doi.org/10.1016/S2468-1253(19)30083-4
  358. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 2018;19:1372-1384. https://doi.org/10.1016/S1470-2045(18)30481-9
  359. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--a randomized phase III trial. J Clin Oncol 2016;34:443-451. https://doi.org/10.1200/JCO.2015.62.6598
  360. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490-499. https://doi.org/10.1016/S1470-2045(13)70102-5
  361. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:481-489. https://doi.org/10.1016/S1470-2045(13)70096-2
  362. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebocontrolled phase III study. J Clin Oncol 2011;29:3968-3976. https://doi.org/10.1200/JCO.2011.36.2236
  363. Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:420-435. https://doi.org/10.1016/S1470-2045(18)30791-5
  364. Catenacci DV, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastrooesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1467-1482. https://doi.org/10.1016/S1470-2045(17)30566-1
  365. Doi T, Kang YK, Muro K, Jiang Y, Jain RK, Lizambri R. A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial. J Clin Oncol 2015;33 3 Suppl:TPS226-TPS226. https://doi.org/10.1200/jco.2015.33.3_suppl.tps226
  366. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol 2017;3:620-627. https://doi.org/10.1001/jamaoncol.2016.5580
  367. Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600:727-730. https://doi.org/10.1038/s41586-021-04161-3
  368. Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:234-247. https://doi.org/10.1016/S1470-2045(21)00692-6
  369. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370
  370. Zhao JJ, Yap DW, Chan YH, Tan BK, Teo CB, Syn NL, et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol 2022;40:392-402. https://doi.org/10.1200/JCO.21.01862
  371. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518. https://doi.org/10.1200/JCO.2011.39.4585
  372. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002
  373. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78-86. https://doi.org/10.1016/S1470-2045(13)70549-7
  374. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 2013;24:2850-2854. https://doi.org/10.1093/annonc/mdt351
  375. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31:4438-4444. https://doi.org/10.1200/JCO.2012.48.5805
  376. Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, et al. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist 2019;24:18-e24.
  377. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39. https://doi.org/10.1016/S0140-6736(13)61719-5
  378. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235. https://doi.org/10.1016/S1470-2045(14)70420-6
  379. Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): a randomized, open-label, phase 3 trial in Asian patients. Cancer 2022;128:995-1003. https://doi.org/10.1002/cncr.34019
  380. Fuchs CS, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 2022;25:197-206. https://doi.org/10.1007/s10120-021-01227-z
  381. Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123-133. https://doi.org/10.1016/S0140-6736(18)31257-1
  382. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-413. https://doi.org/10.1126/science.aan6733
  383. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-10. https://doi.org/10.1200/JCO.19.02105
  384. Cutsem EV. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Ann Oncol 2021;32:S1283-S1346. https://doi.org/10.1016/j.annonc.2021.08.2135
  385. Lee MJ, Hwang IG, Jang JS, Choi JH, Park BB, Chang MH, et al. Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies. Cancer Res Treat 2012;44:235-241. https://doi.org/10.4143/crt.2012.44.4.235
  386. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, et al. Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist 2017;22:1463-1469. https://doi.org/10.1634/theoncologist.2017-0158
  387. Choi IS, Choi M, Lee JH, Kim JH, Suh KJ, Lee JY, et al. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: a population-based outcomes study. PLoS One 2018;13:e0198544.
  388. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1437-1448. https://doi.org/10.1016/S1470-2045(18)30739-3
  389. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5
  390. Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 2020;23:510-519. https://doi.org/10.1007/s10120-019-01034-7
  391. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382:2419-2430. https://doi.org/10.1056/NEJMoa2004413
  392. Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 2021;39:2903-2913. https://doi.org/10.1200/JCO.20.02914
  393. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al.; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 2021;22:1081-1092. https://doi.org/10.1016/S1470-2045(21)00297-7
  394. Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer 2021;24:492-502. https://doi.org/10.1007/s10120-020-01136-7
  395. Kim HD, Lee JS, Yook JH, Ryu MH, Park YK, Kim JY, et al. Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study. Gastric Cancer 2022;25:170-179. https://doi.org/10.1007/s10120-021-01243-z
  396. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol 2010;6:278-285. https://doi.org/10.1111/j.1743-7563.2010.01331.x
  397. Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012;84:e585-e592. https://doi.org/10.1016/j.ijrobp.2012.07.2378
  398. Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012;104:361-366. https://doi.org/10.1016/j.radonc.2012.08.024
  399. Cats A, Jansen EP, van Grieken NC, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616-628. https://doi.org/10.1016/S1470-2045(18)30132-3
  400. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  401. Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016;27:660-667. https://doi.org/10.1093/annonc/mdw010
  402. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017;24:2252-2258. https://doi.org/10.1245/s10434-017-5830-6
  403. Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer 2017;81:183-190. https://doi.org/10.1016/j.ejca.2017.04.027
  404. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856. https://doi.org/10.1200/JCO.2008.17.0506
  405. von Dobeln GA, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis Esophagus 2019;32:32.
  406. Hong J, Chen Y, Li J, Hu P, Chen P, Du N, et al. Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction: an updated systematic review and meta-analysis. Am J Surg 2022;223:1067-1078. https://doi.org/10.1016/j.amjsurg.2021.10.038
  407. Bian SB, Shen WS, Xi HQ, Wei B, Chen L. Palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer: a meta-analysis comparison of gastrojejunostomy with endoscopic stenting. Chin Med J (Engl) 2016;129:1113-1121. https://doi.org/10.4103/0366-6999.180530
  408. Alonso-Larraga JO, Alvaro-Villegas JC, Sobrino-Cossio S, Hernandez-Guerrero A, de-la-Mora-Levy G, Figueroa-Barojas P. Self-expanding metal stents versus antrectomy for the palliative treatment of obstructive adenocarcinoma of the gastric antrum. Rev Esp Enferm Dig 2012;104:185-189. https://doi.org/10.4321/S1130-01082012000400003
  409. Fiori E, Crocetti D, Sapienza P, Cirocchi R, Sterpetti AV, Miccini M, et al. Palliative surgery or metallic stent positioning for advanced gastric cancer: differences in QOL. Medicina (Kaunas) 2021;57:57.
  410. Fiori E, Lamazza A, Volpino P, Burza A, Paparelli C, Cavallaro G, et al. Palliative management of malignant antro-pyloric strictures. Gastroenterostomy vs. endoscopic stenting. A randomized prospective trial. Anticancer Res 2004;24:269-271.
  411. Fiori E, Lamazza A, Demasi E, Decesare A, Schillaci A, Sterpetti AV. Endoscopic stenting for gastric outlet obstruction in patients with unresectable antro pyloric cancer. Systematic review of the literature and final results of a prospective study. The point of view of a surgical group. Am J Surg 2013;206:210-217. https://doi.org/10.1016/j.amjsurg.2012.08.018
  412. Haga Y, Hiki N, Kinoshita T, Ojima T, Nabeya Y, Kuwabara S, et al. Treatment option of endoscopic stent insertion or gastrojejunostomy for gastric outlet obstruction due to gastric cancer: a propensity scorematched analysis. Gastric Cancer 2020;23:667-676. https://doi.org/10.1007/s10120-020-01040-0
  413. Jang SH, Lee H, Min BH, Kim SM, Kim HS, Carriere KC, et al. Palliative gastrojejunostomy versus endoscopic stent placement for gastric outlet obstruction in patients with unresectable gastric cancer: a propensity score-matched analysis. Surg Endosc 2017;31:4217-4223. https://doi.org/10.1007/s00464-017-5480-6
  414. Keranen I, Kylanpaa L, Udd M, Louhimo J, Lepisto A, Halttunen J, et al. Gastric outlet obstruction in gastric cancer: a comparison of three palliative methods. J Surg Oncol 2013;108:537-541. https://doi.org/10.1002/jso.23442
  415. Maetani I, Akatsuka S, Ikeda M, Tada T, Ukita T, Nakamura Y, et al. Self-expandable metallic stent placement for palliation in gastric outlet obstructions caused by gastric cancer: a comparison with surgical gastrojejunostomy. J Gastroenterol 2005;40:932-937. https://doi.org/10.1007/s00535-005-1651-7
  416. No JH, Kim SW, Lim CH, Kim JS, Cho YK, Park JM, et al. Long-term outcome of palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer in patients with good performance status:endoscopic stenting versus surgery. Gastrointest Endosc 2013;78:55-62. https://doi.org/10.1016/j.gie.2013.01.041
  417. Park CH, Park JC, Kim EH, Chung H, An JY, Kim HI, et al. Impact of carcinomatosis and ascites status on long-term outcomes of palliative treatment for patients with gastric outlet obstruction caused by unresectable gastric cancer: stent placement versus palliative gastrojejunostomy. Gastrointest Endosc 2015;81:321-332. https://doi.org/10.1016/j.gie.2014.06.024
  418. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318. https://doi.org/10.1016/S1470-2045(15)00553-7
  419. Shimura T, Kataoka H, Sasaki M, Yamada T, Hayashi K, Togawa S, et al. Feasibility of self-expandable metallic stent plus chemotherapy for metastatic gastric cancer with pyloric stenosis. J Gastroenterol Hepatol 2009;24:1358-1364. https://doi.org/10.1111/j.1440-1746.2009.05857.x
  420. Wang C, Zhang X, Lin S, Yang C, Zhou B, Mi Y, et al. Superiority of laparoscopic gastrojejunostomy combined with multimodality therapy for gastric outlet obstruction caused by advanced gastric cancer. Front Oncol 2022;12:814283.
  421. Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 2021;6:227-240. https://doi.org/10.1002/ags3.12515
  422. Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIOFLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 2017;17:893.
  423. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. https://doi.org/10.1200/JCO.1995.13.1.8
  424. Lavacchi D, Giommoni E, Cianchi F, Antonuzzo L. Treatment strategy for oligometastatic gastric cancer:brief considerations. J Gastrointest Cancer 2022;
  425. Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin Res Hepatol Gastroenterol 2020;44:638-645. https://doi.org/10.1016/j.clinre.2020.02.003
  426. Chen S, Li YF, Feng XY, Zhou ZW, Yuan XH, Chen YB. Significance of palliative gastrectomy for late-stage gastric cancer patients. J Surg Oncol 2012;106:862-871. https://doi.org/10.1002/jso.23158
  427. Miki Y, Fujitani K, Hirao M, Kurokawa Y, Mano M, Tsujie M, et al. Significance of surgical treatment of liver metastases from gastric cancer. Anticancer Res 2012;32:665-670.
  428. Tang K, Zhang B, Dong L, Wang L, Tang Z. Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer. J Int Med Res 2020;48:300060520940509.
  429. Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, et al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis 2014;31:25-32. https://doi.org/10.1007/s10585-013-9606-5
  430. Kim HO, Hwang SI, Hong HP, Yoo CH. Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech 2009;19:208-212. https://doi.org/10.1097/SLE.0b013e3181a033d7
  431. Liu SF, Lu CR, Cheng HD, Xi HQ, Cui JX, Li JY, et al. Comparison of therapeutic efficacy between gastrectomy with transarterial chemoembolization plus systemic chemotherapy and systemic chemotherapy alone in gastric cancer with synchronous liver metastasis. Chin Med J (Engl) 2015;128:2194-2201. https://doi.org/10.4103/0366-6999.162497
  432. Cho JH, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, et al. Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with Krukenberg tumor. Cancer Res Treat 2015;47:697-705. https://doi.org/10.4143/crt.2013.175
  433. Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL, et al. Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 2012;32:3397-3401.
  434. Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, et al. Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 2017;8:82558-82570. https://doi.org/10.18632/oncotarget.19759
  435. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol 2004;94:477-482. https://doi.org/10.1016/j.ygyno.2004.05.007
  436. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009;96:1015-1022. https://doi.org/10.1002/bjs.6665
  437. Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 2014;101:653-660. https://doi.org/10.1002/bjs.9484
  438. Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer 2017;20:322-331. https://doi.org/10.1007/s10120-016-0619-z
  439. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403. https://doi.org/10.1200/JCO.2004.08.154
  440. Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg 2018;2:116-123. https://doi.org/10.1002/ags3.12060
  441. Padmakumar S, Parayath N, Leslie F, Nair SV, Menon D, Amiji MM. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. Expert Opin Drug Deliv 2018;15:481-494. https://doi.org/10.1080/17425247.2018.1446938
  442. Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 2012;105:38-42. https://doi.org/10.1002/jso.22057
  443. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010;21:67-70. https://doi.org/10.1093/annonc/mdp260
  444. Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013;71:1265-1272. https://doi.org/10.1007/s00280-013-2122-0
  445. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. https://doi.org/10.1056/NEJMoa052985
  446. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013;119:3354-3358. https://doi.org/10.1002/cncr.28204
  447. Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN guidelines® insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw 2022;20:972-980. https://doi.org/10.6004/jnccn.2022.0047
  448. Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 2018;36:1922-1929. https://doi.org/10.1200/JCO.2018.77.8613
  449. Lee JK, Park YS, Lee K, Youn SI, Won Y, Min SH, et al. Prognostic significance of surgery-induced sarcopenia in the survival of gastric cancer patients: a sex-specific analysis. J Cachexia Sarcopenia Muscle 2021;12:1897-1907. https://doi.org/10.1002/jcsm.12793
  450. Meng Q, Tan S, Jiang Y, Han J, Xi Q, Zhuang Q, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: a randomized clinical trial. Clin Nutr 2021;40:40-46. https://doi.org/10.1016/j.clnu.2020.04.043
  451. Miyazaki Y, Omori T, Fujitani K, Fujita J, Kawabata R, Imamura H, et al. Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial. Gastric Cancer 2021;24:1150-1159. https://doi.org/10.1007/s10120-021-01188-3
  452. Hu Y, Kim HI, Hyung WJ, Song KJ, Lee JH, Kim YM, et al. Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors. Ann Surg 2013;258:970-975. https://doi.org/10.1097/sla.0000000000000214
  453. Lim CH, Kim SW, Kim WC, Kim JS, Cho YK, Park JM, et al. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. World J Gastroenterol 2012;18:6114-6119. https://doi.org/10.3748/wjg.v18.i42.6114
  454. Jun JH, Yoo JE, Lee JA, Kim YS, Sunwoo S, Kim BS, et al. Anemia after gastrectomy in long-term survivors of gastric cancer: a retrospective cohort study. Int J Surg 2016;28:162-168. https://doi.org/10.1016/j.ijsu.2016.02.084
  455. Kim YW, Bae JM, Park YK, Yang HK, Yu W, Yook JH, et al. Effect of intravenous ferric carboxymaltose on hemoglobin response among patients with acute isovolemic anemia following gastrectomy: the FAIRY randomized clinical trial. JAMA 2017;317:2097-2104. https://doi.org/10.1001/jama.2017.5703
  456. Snook J, Bhala N, Beales IL, Cannings D, Kightley C, Logan RP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut 2021;70:2030-2051. https://doi.org/10.1136/gutjnl-2021-325210
  457. Choi YJ, Choi IY, Jang W, Jeong SM, Park S, Han K, et al. Gastrectomy, vitamin B12 supplementation and the risk of Parkinson's disease: a nationwide cohort study. Parkinsonism Relat Disord 2021;83:15-21. https://doi.org/10.1016/j.parkreldis.2020.12.026
  458. Choi YJ, Shin DW, Jang W, Lee DH, Jeong SM, Park S, et al. Risk of dementia in gastric cancer survivors who underwent gastrectomy: a nationwide study in Korea. Ann Surg Oncol 2019;26:4229-4237. https://doi.org/10.1245/s10434-019-07913-8
  459. Adachi S, Kawamoto T, Otsuka M, Todoroki T, Fukao K. Enteral vitamin B12 supplements reverse postgastrectomy B12 deficiency. Ann Surg 2000;232:199-201. https://doi.org/10.1097/00000658-200008000-00008
  460. Kim HI, Hyung WJ, Song KJ, Choi SH, Kim CB, Noh SH. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Ann Surg Oncol 2011;18:3711-3717. https://doi.org/10.1245/s10434-011-1764-6
  461. Namikawa T, Maeda M, Yokota K, Iwabu J, Munekage M, Uemura S, et al. Enteral vitamin B12 supplementation is effective for improving anemia in patients who underwent total gastrectomy. Oncology 2021;99:225-233. https://doi.org/10.1159/000513888
  462. Atsumi Y, Rino Y, Wada H, Kitani Y, Ozawa Y, Aoyama T, et al. Changes in bone metabolism after gastric cancer surgery in male patients: a prospective observational study. Gastric Cancer 2019;22:237-243. https://doi.org/10.1007/s10120-018-0835-9
  463. Oh HJ, Yoon BH, Ha YC, Suh DC, Lee SM, Koo KH, et al. The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis. Osteoporos Int 2020;31:267-275. https://doi.org/10.1007/s00198-019-05220-2
  464. Rino Y, Takanashi Y, Yamamoto Y, Inagaki D, Kawamoto M, Harada H, et al. Bone disorder and vitamin D after gastric cancer surgery. Hepatogastroenterology 2007;54:1596-1600.
  465. Baek KH, Jeon HM, Lee SS, Lim DJ, Oh KW, Lee WY, et al. Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients. Bone 2008;42:61-67. https://doi.org/10.1016/j.bone.2007.08.027
  466. Shin DW, Suh B, Lim H, Suh YS, Choi YJ, Jeong SM, et al. Increased risk of osteoporotic fracture in postgastrectomy gastric cancer survivors compared with matched controls: a nationwide cohort study in Korea. Am J Gastroenterol 2019;114:1735-1743. https://doi.org/10.14309/ajg.0000000000000436
  467. Yoo SH, Lee JA, Kang SY, Kim YS, Sunwoo S, Kim BS, et al. Risk of osteoporosis after gastrectomy in long-term gastric cancer survivors. Gastric Cancer 2018;21:720-727. https://doi.org/10.1007/s10120-017-0777-7
  468. Ha J, Lee JM, Lim Y, Kim MK, Kwon HS, Song KH, et al. Effect of bisphosphonate on the prevention of bone loss in patients with gastric cancer after gastrectomy: a randomized controlled trial. Bone 2020;130:115138.
  469. Lamb B, Green JS, Vincent C, Sevdalis N. Decision making in surgical oncology. Surg Oncol 2011;20:163-168. https://doi.org/10.1016/j.suronc.2010.07.007
  470. Stephens MR, Lewis WG, Brewster AE, Lord I, Blackshaw GR, Hodzovic I, et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus 2006;19:164-171. https://doi.org/10.1111/j.1442-2050.2006.00559.x
  471. Xiang YY, Deng CC, Liu HY, Kuo ZC, Zhang CH, He YL. The prognostic effect of multidisciplinary team intervention in patients with advanced gastric cancer. Curr Oncol 2022;29:1201-1212. https://doi.org/10.3390/curroncol29020102
  472. Di L, Wu H, Zhu R, Li Y, Wu X, Xie R, et al. Multi-disciplinary team for early gastric cancer diagnosis improves the detection rate of early gastric cancer. BMC Gastroenterol 2017;17:147.
  473. Yuan Z, Weng S, Ye C, Hu H, Zhang S, Yuan Y. CSCO guidelines for colorectal cancer version 2022:updates and discussions. Chin J Cancer Res 2022;34:67-70. https://doi.org/10.21147/j.issn.1000-9604.2022.02.01
  474. Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, et al. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg 2014;149:18-25. https://doi.org/10.1001/jamasurg.2013.3959
  475. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27 Suppl 5:v38-v49. https://doi.org/10.1093/annonc/mdw350
  476. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet 2016;388:2654-2664. https://doi.org/10.1016/S0140-6736(16)30354-3
  477. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMOESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi57-vi63. https://doi.org/10.1093/annonc/mdt344
  478. Basta YL, Baur OL, van Dieren S, Klinkenbijl JH, Fockens P, Tytgat KM. Is there a benefit of multidisciplinary cancer team meetings for patients with gastrointestinal malignancies? Ann Surg Oncol 2016;23:2430-2437. https://doi.org/10.1245/s10434-016-5178-3
  479. Basta YL, Bolle S, Fockens P, Tytgat KM. The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: a systematic review. Ann Surg Oncol 2017;24:2669-2678. https://doi.org/10.1245/s10434-017-5833-3
  480. Du CZ, Li J, Cai Y, Sun YS, Xue WC, Gu J. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol 2011;17:2013-2018. https://doi.org/10.3748/wjg.v17.i15.2013
  481. Oxenberg J, Papenfuss W, Esemuede I, Attwood K, Simunovic M, Kuvshinoff B, et al. Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol 2015;22:1533-1539. https://doi.org/10.1245/s10434-014-4163-y
  482. Lamb BW, Sevdalis N, Arora S, Pinto A, Vincent C, Green JS. Teamwork and team decision-making at multidisciplinary cancer conferences: barriers, facilitators, and opportunities for improvement. World J Surg 2011;35:1970-1976. https://doi.org/10.1007/s00268-011-1152-1
  483. Lamb BW, Jalil RT, Sevdalis N, Vincent C, Green JS. Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care: a survey study. BMC Health Serv Res 2014;14:377.
  484. Chinai N, Bintcliffe F, Armstrong EM, Teape J, Jones BM, Hosie KB. Does every patient need to be discussed at a multidisciplinary team meeting? Clin Radiol 2013;68:780-784. https://doi.org/10.1016/j.crad.2013.02.011
  485. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011;60:1449-1472. https://doi.org/10.1136/gut.2010.228254
  486. Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, et al. TELEMAM: a cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making. Eur J Cancer 2007;43:2506-2514. https://doi.org/10.1016/j.ejca.2007.08.026
  487. Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, et al. Establishment of a new prostate cancer multidisciplinary clinic: format and initial experience. Prostate 2015;75:191-199. https://doi.org/10.1002/pros.22904
  488. Kelly SL, Jackson JE, Hickey BE, Szallasi FG, Bond CA. Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. Am J Otolaryngol 2013;34:57-60. https://doi.org/10.1016/j.amjoto.2012.08.010
  489. Pawlik TM, Laheru D, Hruban RH, Coleman J, Wolfgang CL, Campbell K, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 2008;15:2081-2088. https://doi.org/10.1245/s10434-008-9929-7
  490. Santoso JT, Schwertner B, Coleman RL, Hannigan EV. Tumor board in gynecologic oncology. Int J Gynecol Cancer 2004;14:206-209. https://doi.org/10.1111/j.1048-891X.2004.014200.x
  491. Borneman T, Koczywas M, Cristea M, Reckamp K, Sun V, Ferrell B. An interdisciplinary care approach for integration of palliative care in lung cancer. Clin Lung Cancer 2008;9:352-360. https://doi.org/10.3816/CLC.2008.n.051